RegisterLogin

Ticagrelor

CAT: 0804-HY-10064-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10064-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
CAS Number
[274693-27-5]
Product Name Alternative
AZD6140; AR-C 126532XX
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
P2Y Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Ticagrelor.html
Purity
99.98
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
P2Y12 Receptor

Related Products

CatalogName

Alternative Products

CatalogName
021849Ticagrelor
RM-T030701-01Ticagrelor Impurity A (Ticagrelor Enantiomer)
RM-T030702-01Ticagrelor Impurity B (Ticagrelor Isomer 2)
T204547-01Deshydroxyethoxy ticagrelor
MBS6032257-01Ticagrelor-d7
TRC-D232265-10MGTicagrelor Acetate

Popular Products